source
- AstraZeneca and Amgen report positive Phase 3 results for Tezspire in eosinophilic esophagitisAstraZeneca and Amgen announced that their joint drug Tezspire met primary and secondary endpoints in a late-stage Phase 3 trial for eosinophilic esophagitis. The antibody targets TSLP and had pre…
- FDA greenlights first oral therapy for adult dermatomyositisThe U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as a treatment for adults with dermatomyositis. Dermatomyositis is a rare autoimmune condition that attacks muscle…